MSD has successfully tested a new pneumococcal vaccine

MSD has published the results of clinical trials of a 15-valent vaccine against pneumococcus. The data obtained are so convincing that the company is preparing to submit registration applications to regulatory authorities around the world, says FiercePharma.

At the same time was presented the data of the two studies: among persons over the age of 18 living with HIV, and patients older than 50 years who also received injections of the vaccine it protects against the flu. In both studies, candidate vaccine V114 contributed to the development of immune response against all 15 serotypes of pneumococcus.

Development MSD competes with experimental pneumococcal vaccine Pfizer intended for prevention of infection of 20 serotypes of streptococcus pneumoniae. Pfizer presented the results of a clinical phase III studies in March and also preparing for the filing of the registration statement.

Leave a Reply

Your email address will not be published. Required fields are marked *


The largest pharmaceutical companies refuse advertising in Facebook

A number of international pharmaceutical manufacturers joined the campaign Stop Hate for Profit, in which brands refuse advertising in Facebook. Pfizer, Novartis and AbbVie announced the termination of the advertising placements on the social network in July, reports FiercePharma. The purpose of the traffic Stop Hate for Profit is putting pressure on the social network […]

In Russia confirmed 6 718 new cases COVID-19

A day in Russia revealed 6 718 new cases of coronavirus infection in 84 regions. In 32,5% of patients there are no clinical manifestations of the disease. The day passed away 176 people, was fully recovered 8 915 patients. In Moscow confirmed 659 new cases COVID-19. This is 89% less than 2 months ago, may […]